Recent Updates — NBTX

Nanobiotix announced final data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors for anti-PD-1-resistant primary cutaneous melanoma. In 24 heavily pre-treated patients, the treatment showed an overall response rate of 41.7% and a disease control rate of 75%, with a median overall survival of 17.8 months. The safety profile was acceptable, and exploratory analysis identified IL-1β as the most increased plasma cytokine. These preliminary findings support further evaluation in randomized clinical trials. Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches for cancer.

Nanobiotix S.A. announced the appointment of Arnd Christ as Chief Financial Officer and member of the executive board, effective October 1, 2026. Mr. Christ succeeds Bart Van Rhijn, who served in the role for five years before stepping down. Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches to treat cancer and other major diseases.

Nanobiotix S.A. reported a net loss of €34.3 million for the six months ended June 30, 2026, compared to a net loss of €5.4 million in the prior year period. Revenue declined significantly to €5.6 million from €26.6 million, primarily due to the absence of a €21.2 million one-off positive revenue adjustment recognized in H1 2025 related to a contract modification with Janssen Pharmaceutica NV. Operating expenses decreased by €2.4 million to €23.5 million, driven by lower clinical study costs following the transfer of sponsorship for the NANORAY-312 trial and reduced patient recruitment. The financial result worsened due to increased interest costs totaling €14.5 million, largely attributable to fixed-rate interest on a royalty financing agreement with HealthCare Royalty Partners. In May 2026, the company completed an oversubscribed follow-on equity offering raising €86.0 million in gross proceeds, including pre-funded warrants. The company operates as a late-stage clinical biotechnology firm developing physics-based nanotherapeutic platforms for oncology and neurological diseases.

Nanobiotix S.A. reported first-half 2026 financial results and operational updates, posting a net loss of €34.3 million (€0.70 basic loss per share) compared to €5.4 million in the prior year period. Revenue declined to €5.6 million from €26.6 million, primarily due to a €21.2 million one-off non-cash revenue item recorded in H1 2025 following the transfer of NANORAY-312 study sponsorship to Johnson & Johnson. The company holds €110.9 million in cash and cash equivalents as of June 30, 2026, extending its runway into 2029. Clinically, Nanobiotix presented promising early results from a Phase 1 NSCLC study showing a one-year overall survival rate of 70% and acceptable safety data from the J&J-led Phase 2 CONVERGE study in Stage 3 NSCLC. Additionally, the U.S. FDA cleared a protocol amendment for the Phase 3 NANORAY-312 head and neck cancer study to streamline the final analysis. Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based nanotherapeutic approaches for oncology.

Nanobiotix announced complete Phase 1 results for JNJ-1900 (NBTXR3) in patients with inoperable, recurrent non-small cell lung cancer. All 24 evaluable subjects completed treatment with no dose-limiting toxicities or Grade 3+ adverse events related to the drug or injection procedure. One-year locoregional control was 79%, local progression-free survival was 61%, and overall survival was 70%. The study established a recommended Phase 2 dose at 33% of gross tumor volume, demonstrating clinically meaningful local control at substantially lower re-irradiation doses than prior courses. Enrollment in the dose-escalation and expansion phases is complete, with additional patient enrollment planned. Nanobiotix operates as a late-stage clinical biotechnology company pioneering physics-based nanotechnology approaches to expand cancer treatment possibilities.